Currently, there are 48.53M common shares owned by the public and among those 41.69M shares have been available to trade.
The company’s stock has a 5-day price change of 2.51% and 70.83% over the past three months. SLNO shares are trading 71.06% year to date (YTD), with the 12-month market performance up to 73.68% higher. It has a 12-month low price of $36.93 and touched a high of $80.99 over the same period. SLNO has an average intraday trading volume of 1.32 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.43%, 13.06%, and 41.76% respectively.
Institutional ownership of Soleno Therapeutics Inc (NASDAQ: SLNO) shares accounts for 95.55% of the company’s 48.53M shares outstanding.
It has a market capitalization of $3.87B and a beta (3y monthly) value of -2.70. The earnings-per-share (ttm) stands at -$4.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.70% over the week and 1.86% over the month.
Earnings per share for the fiscal year are expected to increase by 36.23%, and 128.72% over the next financial year.
Looking at the support for the SLNO, a number of firms have released research notes about the stock. Stifel stated their Buy rating for the stock in a research note on March 05, 2025, with the firm’s price target at $74. Stifel coverage for the Soleno Therapeutics Inc (SLNO) stock in a research note released on December 02, 2024 offered a Buy rating with a price target of $74. Robert W. Baird was of a view on December 02, 2024 that the stock is Outperform, while H.C. Wainwright gave the stock Buy rating on September 03, 2024, issuing a price target of $70. Robert W. Baird on their part issued Outperform rating on May 10, 2024.
